Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cumulative Live Birth Rate With eSET After Preimplantation Genetic Screening Versus Conventional In-vitro Fertilization (CESE-PGS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03118141
Recruitment Status : Recruiting
First Posted : April 18, 2017
Last Update Posted : September 20, 2019
Sponsor:
Collaborators:
The First Affiliated Hospital with Nanjing Medical University
Peking University Third Hospital
ShangHai Ji Ai Genetics & IVF Institute
RenJi Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Suzhou Municipal Hospital
Renmin Hospital of Wuhan University
Yantai Yuhuangding Hospital
Tang-Du Hospital
Nanjing Maternity and Child Health Care Hospital
Guangxi Maternal and Child Health Hospital
Women's Hospital School Of Medicine Zhejiang University
Guangdong Women and Children Hospital
Tianjin Central Hospital of Gynecology Obstetrics
Shengjing Hospital
The First Affiliated Hospital of Anhui Medical University
Information provided by (Responsible Party):
Chen Zi-Jiang, Shandong University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this randomized clinical trial is to compare the efficacy and safety with transfer of embryos selected by next generation sequencing (NGS) versus conventional morphological criteria. Subjects with 3 or more blastocysts on day 5 of embryo culture will be randomized to the PGS or IVF group. A Freeze-all strategy and a single frozen blastocyst transfer will be performed in both PGS and IVF groups. The primary outcome is the cumulative live birth after transfers of up to 3 single blastocycsts in both groups.

Condition or disease Intervention/treatment Phase
Infertility Procedure: blastocyst morphologic score Procedure: blastocyst biopsy and sequencing Procedure: freeze-all and single thawed blastocyst transfer Not Applicable

Detailed Description:
This is a multicenter, randomized clinical trial comparing the efficacy and safety with transfer of embryos selected by next generation sequence (NGS) and morphologic criteria versus by morphological criteria alone. Subjects who obtain 3 or more good-quality blastocysts will be randomized to PGS or IVF group. All embryos will be frozen and a single thawed blastocyst will be transferred in both PGS and IVF group. Subjects in the PGS group will have 3 blastocysts sequenced and euploid embryos will be subsequently transferred. Subjects in the IVF group will have blastocysts selected by morphology assessment. The cumulative live birth rate will be counted after transfers of all euploid embryo in the PGS group and 3 blastocysts in the IVF group within 1 year after randomization.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1215 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cumulative Live Birth Rate With eSET After In-vitro Fertilization With Preim-plantation Genetic Screening by Next Generation Sequencing Versus Conventional In-vitro Fertilization: A Pragmatic Randomized Controlled Clinical Trial
Actual Study Start Date : July 9, 2017
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2020
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: PGS group
Subjects in the PGS group will have blastocyst biopsy and sequencing done with 3 good-quality embryos on Day 5. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by blastocyst morphologic score. The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
 Procedure: blastocyst morphologic score
Blastocysts will be scored by Gardner morphologic criteria.

Procedure: blastocyst biopsy and sequencing
Three blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.

Procedure: freeze-all and single thawed blastocyst transfer
All blastocysts will be vitrified in fresh cycle. Single blastocyst will be thawed and transferred.
Active Comparator: IVF group
Subjects in the IVF group will also comply with the principle of freeze-all and single thawed blastocyst transfer. The order of transfer will be determined by blastocyst morphologic score. The outcome of up to 3 transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
 Procedure: blastocyst morphologic score
Blastocysts will be scored by Gardner morphologic criteria.

Procedure: freeze-all and single thawed blastocyst transfer
All blastocysts will be vitrified in fresh cycle. Single blastocyst will be thawed and transferred.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Cumulative live birth rate [ Time Frame: 22 months ]
    Live birth is defined as the delivery of any viable infant at 28 weeks or more of gestation after our interventions, and cumulative live birth rate is calculated by dividing the number of women achieving live birth after transfers of all study-specific embryos (up to 3 transfers of single blastocycst within 1 year after randomization), by the total number of women randomized to the specific group.


Secondary Outcome Measures :
  1. Rate of Good Birth Outcomes [ Time Frame: 22 months ]
    Number of good birth outcomes / number of clinical pregnancies over (up to) 3 transfers within 1 year.Good Birth Outcome is defined as live birth of an infant born at ≥ 37 weeks, with a birth weight between 2500 and 4000g and without a major congenital anomaly.

  2. Cumulative pregnancy rate [ Time Frame: 14 months ]
    Number of women with clinical pregnancies over (up to) 3 transfers within 1 year / number of women randomized to the specific group. Clinical pregnancy will be diagnosed with detection of an intrauterine gestational sac.

  3. Cumulative pregnancy loss rate [ Time Frame: 19 months ]
    Number of pregnancy losses / number of clinical pregnancies over (up to) 3 transfers within 1 year.Pregnancy loss refers to a complete spontaneous abortion or a nonviable pregnancy before 28 weeks of gestation.

  4. Multiple pregnancy rate [ Time Frame: 22 months ]
    Number of multiple pregnancies / number of clinical pregnancies over (up to) 3 transfers within 1 year.

  5. Duration of pregnancy [ Time Frame: 22 months ]
    The time from the first day of last menstrual period to the day of delivery.

  6. Birth weight [ Time Frame: 22 months ]
    Weight of newborns at delivery.

  7. Cumulative incidence of maternal and neonatal complications during whole gestation and prenatal stage [ Time Frame: 22 months ]
    Number of pregnancies with complications / number of pregnancies over (up to) 3 transfers within 1 year;number of live births with neonatal complications / number of live births over (up to)3 transfers within 1 year.

  8. Number of embryo transfers to achieve live birth [ Time Frame: 22 months ]
    Number of embryo transfers the patients have gone through to achieve live birth.


Other Outcome Measures:
  1. Clinical pregnancy rate after the first transfer [ Time Frame: 4 months ]
    Number of women with clinical pregnancies after the first transfer / number of women randomized to the specific group.

  2. Pregnancy loss rate after the first transfer [ Time Frame: 9 months ]
    Number of pregnancy losses / number of clinical pregnancies after the first transfer .

  3. Live birth rate after the first transfer [ Time Frame: 12 months ]
    Number of women with live births after the first transfer / number of women randomized to the specific group.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 37 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Women who are participating in their first cycle of IVF or ICSI
  2. Women ages 20 to 37 years.
  3. Women who obtain 3 or more good-quality blastocysts defined as morphological score of inner cell mass B or A, trophectoderm C or better, and grade 4 or better on day 5 of embryo culture will be randomized.

Exclusion Criteria:

  1. Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s); or with history of intrauterine adhesions.
  2. Women with untreated hydrosalpinx;
  3. Women who are indicated and planned to undergo PGD, for example, parental abnormal karyo-type or diagnosed with monogenic disease;
  4. Women who use donated oocytes or sperm to achieve pregnancy;
  5. Women with contraindication for assisted reproductive technology or for pregnancy, such as poorly controlled Type I or Type II diabetes; undiagnosed liver disease or dysfunction (based on se-rum liver enzyme testing); renal disease or abnormal serum renal function; significant anemia; history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident; uncontrolled hyper-tension, known symptomatic heart disease; history of or suspected cervical carcinoma, endometrial carcinoma, or breast carcinoma; undiagnosed vaginal bleeding.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03118141


Contacts
Layout table for location contacts
Contact: Zi-Jiang Chen, Professor +0086 531 85651190 chenzijiang@vip.163.com

Locations
Layout table for location information
China, Shandong
Shandong University Recruiting
Jinan, Shandong, China
Contact: Zi-Jiang Chen, Professor    +0086 531 85651190    chenzijiang@vip.163.com   
Sponsors and Collaborators
Chen Zi-Jiang
The First Affiliated Hospital with Nanjing Medical University
Peking University Third Hospital
ShangHai Ji Ai Genetics & IVF Institute
RenJi Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Suzhou Municipal Hospital
Renmin Hospital of Wuhan University
Yantai Yuhuangding Hospital
Tang-Du Hospital
Nanjing Maternity and Child Health Care Hospital
Guangxi Maternal and Child Health Hospital
Women's Hospital School Of Medicine Zhejiang University
Guangdong Women and Children Hospital
Tianjin Central Hospital of Gynecology Obstetrics
Shengjing Hospital
The First Affiliated Hospital of Anhui Medical University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Chen Zi-Jiang, Professor, Shandong University
ClinicalTrials.gov Identifier: NCT03118141    
Other Study ID Numbers: CESE-PGS
First Posted: April 18, 2017    Key Record Dates
Last Update Posted: September 20, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Chen Zi-Jiang, Shandong University:
preimplantation genetic screening
single embryo transfer
frozen embryo transfer
cumulative live birth rate
Additional relevant MeSH terms:
Layout table for MeSH terms
Infertility